ЭНДОКРИННАЯ ОФТАЛЬМОПАТИЯ: ЭТИОЛОГИЯ, ПАТОГЕНЕЗ, КЛИНИКА, ДИАГНОСТИКА
Аннотация
Актуальность изучения эндокринной офтальмопатии обусловлена большой распространенностью заболевания и высоким риском развития нарушения функций зрения, приводящей к инвалидизации пациентов. Рассматриваются основные генетические, иммунологические, клинические проявления эндокринной офтальмопатии с целью совершенствования диагностики и лечения данной патологии. Клиническая картина эндокринной офтальмопатии многообразна, уникальна для каждого пациента и зависит от активности и тяжести процесса, что требует комбинированной этиопатогенетической терапии. Высока важность своевременного диагностического поиска эндокринной офтальмопатии с оценкой активности процесса для выбора правильной тактики лечения пациентов.
Литература
Brovkina AF. `Endokrinnaja oftalmopatija [Endocrine ophthalmopathy]. Moskva: GEOTAR-MED; 2004. 176 р. (Russian).
Dedov II. `Endokrinologija. Natsionalnoe rukovodstvo [Endocrinology. National leadership]. Moskva: GEOTAR-Media; 2013. 1064 р. (Russian).
Petunina NA, Truhina LV, Martirosjan NS. `Endokrinnaja oftalmopatija: sovremennyj vzgljad [Endocrine ophthalmopathy: state-of-the-art approaches]. Problemy `endokrinologii [Problems of endocrinology]. 2012;6:24-32. (Russian).
Fadeev VV, Melnichenko GA. Bolezn Grejvsa. [Graves’ disease]. Russkij medicinskij zhurnal [Russian medical journal]. 2005;13(6):353-356. (Russian).
Dedov II, Melnichenko GA, Sviridenko NJu, Troshina EA, Fadeev VV, Belovalova IM, Sheremeta MS, Rumjancev PO, Petunina NA, Grineva EN, Strongin LG, Neroev VV, Katargina LA, Saakjan SV, Panteleeva OG, Valskij VV, Brovkina AF, Atarshhikov DS, Bessmertnaja EG, Lipatov DV, Astahov JuS, Sejdasheva JeI, Zolotarev AV, Dogadova LI. Federalnye klinicheskie rekomendatsii po diagnostike i lecheniju `endokrinnoj oftalmopatii pri autoimmunnoj patologii schitovidnoj zhelezy [Federal clinical recommendations on diagnostics and treatment of endocrine ophthalmopathy associated with autoimmune thyroid pathology]. Problemy `endokrinologii [Problems of endocrinology]. 2015;1:61-74. (Russian).
Wiersinga WM, Smit T, van der Gaag R, Koornneef L. Temporal relationship between onset of Graves’ ophthalmopathy and onset of thyroidal Graves’ disease. J Endocrinol Invest. 1988;11(8):615-619. doi: 10.1007/BF03350193.
Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County. Trans. Am. Ophthal. Soc. 1994;92:477-588.
Holodova ЕА. Spravochnik po klinicheskoj `endokrinologii [Handbook of clinical endocrinology]. Minsk: Belarus; 1998. 511 p. (Russian).
Khoo DH, Eng PH, Ho SC, Tai ES, Morgenthaler NG, Seah LL, Fong KS, Chee SP, Choo CT, Aw SE. Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid. 2000;10(12):1093-1100. doi: 10.1089/thy.2000.10.1093.
Danilova LI, Birich ТА. Autoimmunnaja oftalmopatija [Autoimmune ophthalmopathy]. Medicinskie novosti [Medical news]. 1995;5:8-19. (Russian).
Grechanyj MP, Chentsova ОВ, Kildjushevskij AV. `Etiologija, patogenez i perspektivy lechenija autoimmunnyh zabolevanij glaz [Etiology, pathogenesis and prospects for treating autoimmune eye diseases]. Vestnik oftalmologii [Vestnik otorinolaringologii]. 2002;5:47-51. (Russian).
Brovkina AF. Sovremennye aspekty patogeneza i lechenija `endokrinnoj oftalmopatii [Recent aspects of pathogenesis and treatment of endocrine ophthalmopathy]. Vestnik Rossijskoj akademii medicinskih nauk [Annals of the Russian academy of medical sciences]. 2003;5:52-54. (Russian).
Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of Graves’ Orbitopathy. Eur. J. Endocrinol. 2008;158(3):273-285. doi: 10.1530/EJE-07-0666.
Okorokov AN. Diagnostika boleznej vnutrennih organov [Diagnosis of internal diseases]. Vol. 2, Revmaticheskie i sistemnye zabolevanija soedinitel’noj tkani. Bolezni jendokrinnoj sistemy. Vitebsk: Belmedkniga; 1998. 576 p. (Russian).
Prummel MF, Wiersinga WM. Smoking and risk of Graves’ disease. JAMA. 1993;269(4):479-482.
Bartalena L, Tanda ML, Piantanida E, Lai A, Pinchera A. Relationship between management of hyperthyroidism and course of the ophthalmopathy. J. Endocrinol. Invest. 2004;27(3):288-294. doi: 10.1007/BF03345279.
Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link. J. Clin. Endocrinol. Metab. 2007;92(1):59-64. doi: 10.1210/jc.2006-1824.
Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Thyroid Study Group. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N. Engl. J. Med. 1992;326(26):1733-1738. doi: 10.1056/NEJM199206253262603.
Wiersinga WM. Preventing Graves ophthalmopathy. N. Engl. J. Med. 1998;338(2):121-122. doi: 10.1056/NEJM199801083380209.
Brovkina AF. Bolezni orbity [Diseases of the orbit a guide for physicians]. Moskva: Medicinskoe informacionnoe agentstvo; 2008. 256 р. (Russian).
Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves’ disease, and thyroid associated ophthalmopathy. Thyroid. 2008;18(9):953-958. doi: 10.1089/thy.2007.0405.
Griepentrog G J, Garrity JA. Update on the medical treatment of Graves’ ophthalmopathy. Int. J. Gen. Med. 2009;2:263-269.
Naik VM, Naik MN, Goldberg RA, Smith TJ, Douglas RS. Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv. Ophthalmol. 2010;55(3):215-226. doi: 10.1016/j.survophthal.2009.06.009.
Bahn Rebecca S. Pathogenesis of Graves’ ophthalmopathy: the role of orbital thyroid-stimulating hormone receptor expression. Current Opinion in Endocrinology & Diabetes. 2003;10(5):353-356.
Takamura Y, Nakano K, Uruno T, Ito Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma K, Miyauchi A. Changes in serum TSH-receptor antibody values in patients with Graves’ Disease after total or subtotal thyroidectomy. Endocr. J. 2003;50(5):595-601.
Leclere J, Bene MC, Aubert V, Klein M, Pascal-Vigneron V, Weryha G, Faure G. Clinical consequences of activating germline mutations of TSH receptor, the concept of toxic hyperplasia. Horm. Res. 1997. 47(4-6):158-162.
Eckstein AK, Plicht M, Lax H, Neuhдuser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG. Thyrotropin Receptor Autoantibodies Are Independent Risk Factors for Graves’ Ophthalmopathy and Help to Predict Severity and Outcome of the Disease. J. Clin. Endocrinol. Metab. 2006;91(9):3464-3470. doi: 10.1210/jc.2005-2813.
Khoo TK, Bahn RS. Pathogenesis of Graves’ ophthalmopathy: the role of autoantibodies. Thyroid. 2007;17(10):1008-1013.
Wall J, Barsouk A, Stolarski C, Kiljanski J, Stachura I, Nebes V, Peele K, Volpe R, Kennerdell J. Serum Antibodies Reactive with Eye Muscle Antigens and the TSH Receptor in a Euthyroid Subject Who Developed Ophthalmopathy and Graves’ Hyperthyroidism. Thyroid. 1996;6(4):353-358. doi: 10.1089/thy.1996.6.353.
Goh SY, Ho SC, Seah LL, Fong KS, Khoo DHC. Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves’ disease differ and suggest ophthalmopathy is a multiantigenic disease. Clinical Endocrinology. 2004;60(5):600-607. doi: 10.1111/j.1365-2265.2004.02033.x.
Wiersinga WM, Kahaly GJ, editor. Graves’ Orbitopathy: Multidisciplinary Approach. Basel: KARGER; 2007. 260 р. doi: 10.1159/isbn.978-3-8055-8343-5.
Lihvantseva VG. K voprosu o roli antitel k tireoperoksidaze pri `endokrinnoj oftal’mopatii [The role of antibodies to tireoperoksidaze when autoimmune orbitopathy]. Rossijskij mediko-biologicheskij vestnik imeni akademika I. P. Pavlova. [Russian medico-biological Bulletin named after academician I. P. Pavlov]. 2011;4:104-110. (Russian).
Mourits МР, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br. J. Ophthalmol. 1989;73(8):639-644.
Samohvalova NM. Sovremennye vzgljady na etiopatogenez, terminologiju i klinicheskie formy `endokrinnoj oftalmopatii [Current views on the etiopathogenesis, terminology and clinical forms of endocrine ophthalmop athy]. Problemy zdorovja i ekologii [Problems of health аnd ecology]. 2013;4:59-63. (Russian).
Balabolkin MI, Klebanova ЕМ, Kreminskaja VM. Fundamentalnaja i klinicheskaja tiroidologija [Fundamental and clinical thyroidology]. Moskva: Medicina; 2007. 492 р. (Russian).
Bahn, RS. Graves’ ophthalmopathy. N. Engl. J. Med. 2010;362(8):726-738. doi: 10.1056/NEJMra0905750.
Mirkievicz-Sieradzka B, Pacura M. Okulistyczne aspekty leczenia neuropatii nerwa wzrokowego w przebilgy oftalmopatii Graves-Basedowa Pacura. Przegl. Lek. 2000;57(6):307-312. (Polish).
Brovkina AF, Jurovskaja NN, Tjutjunnikova АМ. Klassifikatsija i klinicheskie osobennosti `endokrinnoj oftalmopatii [Classification and clinical characteristics of endocrine ophthalmopathy]. Vestnik oftalmologii [Vestnik oftalmologii]. 1983;1:40-43. (Russian).
Brovkina AF, Stojuhina AS. Klassifikatsija endokrinnoj oftalmopatii [Classification of endocrine ophthalmopathy]. Problemy Endokrinologii [Problems of endocrinology]. 2006; 52(5): 11-14. (Russian).
Utech CI, Khatibnia U, Winter PF, Wulle KG. MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves’ ophthalmopathy. Thyroid. 1995;5(3):185-193. doi: 10.1089/thy.1995.5.185.
Prummel MF, Suttorp-Schulten MSA, Wiersinga WM, Verbeek AdM, Mourits MPh, Koornneef Leo. A New Ultrasonographic Method to Detect Disease Аctivity and Predict Response to immunosuppressive Treatment in Graves Ophthalmopathy. 1993;100(4):556-561. doi: 0.1016/S0161-6420(93)31607-6.
Bogomazova EV, Mohort TV. Osobennosti diagnostiki i lechenija autoimmunnoj oftal’mopatii, assotsiirovannoj s patologiej shhitovidnoj zhelezy [Features of diagnosis and treatment of autoimmune ophthalmopathy associated with thyroid pathology] Problemy zdorovja i ekologii. [Problems of health аnd е cology]. 2012(3):69-75. (Russian).
Vorontsov AV. Vozmozhnosti magnitno-rezonansnoj vizualizatsii orbit v diagnostike `endokrinnoj oftalmopatii [The potential of magnetic resonance visualization of the orbits for diagnostics of endocrine ophthalmopathy]. Problemy endokrinologii. [Problems of endocrinology]. 2013;5:3-8. (Russian).
Bogomazova EV, Mohort TV, Marchenko LN, Birich TA, Shepel’kevich AP; Ministerstvo zdravoohranenija Respubliki Belarus. Diagnostika i lechenie autoimmunnoj orbitopatii, assotsiirovannoj s patologiej schitovidnoj zhelezy [Diagnosis and treatment of autoimmune orbitopathy associated with thyroid pathology]. Instrukcija po primeneniju № 082-0610. Minsk; 2010. 21 p. (Russian).
Wiersinga WM, Prummel MF, Terwee CB. Effects of Graves’ ophthalmopathy on quality of life. J. Endocrinol. Invest. 2004;27(3):259-264.
